
|Articles|March 31, 2023
Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 3
Benjamin McLeod, Technical Lead, Virica Biotech, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.
Advertisement
Benjamin serves as Technical Lead with Virica Biotech, a yield-enhancing solution for viral vector and cell therapy production. He is trained in cell biology, biotechnology, and viral vector production. You can find him on LinkedIn, where he regularly posts industry insights and curates papers on process development in CGT.
Register for the full webcast:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
2
Generative AI and Adaptive Trials Shape Future Biotech Development
3
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
4



